Albany, NY -- (SBWIRE) -- 04/02/2014 -- The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
View Full Report With TOC: http://www.researchmoz.us/pancreatic-adenocarcinoma-therapeutics-market-in-major-developed-markets-to-2019-early-stage-pipeline-shows-diversity-of-novel-targets-though-commercial-impact-remains-distant-report.html
The global pancreatic adenocarcinoma therapeutics market is expected to grow from approximately $856m in 2012 to $1.2 billion in 2019, with growth driven by small changes in multiple factors. These include the impact of the drugs approved in the forecast period, but also the increase in the prevalence of the disease and minor improvements in diagnostics that result in more patients being eligible for pharmacological.
A brief introduction to pancreatic adenocarcinoma, including the disease’s pathogenesis, risk factors, diagnosis, staging and treatment algorithms for each stage.
In-depth analysis of drugs available for the treatment of pancreatic adenocarcinoma, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.
Comprehensive review of the pipeline for pancreatic adenocarcinoma therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, program type.
Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain.
Discussion of the drivers and barriers for market growth.
Discussion of the licensing and co-development deals landscape in pancreatic adenocarcinoma, Includes an analysis of licensing deals by stage of development, molecule type and mechanism of action. Also includes an analysis of both licensing and co-development deals by year and value and network maps of licensing and co-development deals.
Find More Reports Related to Theraputic Area: http://www.researchmoz.us/therapeutic-area-market-reports-37.html
Reasons to Buy
Understand the vast scope and diversity of the pipeline, including which molecule types and mechanisms of action are prominent.
Observe the trends in clinical trial duration and size amongst clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for pancreatic adenocarcinoma therapeutics.
Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the pancreatic adenocarcinoma therapeutics market.
HIV Therapeutics Market to 2019 ( http://www.researchmoz.us/hiv-therapeutics-market-to-2019-limited-pipeline-efficacy-improvement-patent-expirations-and-stringent-healthcare-spending-to-suppress-market-growth-report.html )
The report analyzes the market for HIV therapeutics in eight major markets of the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), Japan and Canada. The report discusses the global pipeline for all the HIV molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Research team of industry experts.
Smoking Cessation Products - US - March 2014 ( http://www.researchmoz.us/smoking-cessation-products-us-march-2014-report.html )
E-cigarettes are the latest threat to the beleaguered smoking cessation products’ market. Prior to the rapid arrival and use of e-cigarettes, the fast-following introduction by private label manufacturers of every new product innovation launched by national brands helped commoditize the market and erode dollar sales growth. Future innovation should focus on smaller, cheaper product offerings that position cessation products for sale in new distribution channels, such as convenience stores, where most cigarettes and e-cigarettes are sold.
ResearchMoz ( http://www.researchmoz.us/ ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.
For More Information Kindly Contact:
Toll Free: 866-997-4948